Ulcerative Colitis and Acute Severe Ulcerative Colitis Patients Are Overlooked in Infliximab Population Pharmacokinetic Models: Results from a Comprehensive Review
Ulcerative colitis (UC) is part of the inflammatory bowels diseases, and moderate to severe UC patients can be treated with anti-tumour necrosis α monoclonal antibodies, including infliximab (IFX). Even though treatment of UC patients by IFX has been in place for over a decade, many gaps in modellin...
Saved in:
Main Authors: | Alix Démaris (Author), Ella S. K. Widigson (Author), Johan F. K. F. Ilvemark (Author), Casper Steenholdt (Author), Jakob B. Seidelin (Author), Wilhelm Huisinga (Author), Robin Michelet (Author), Linda B. S. Aulin (Author), Charlotte Kloft (Author) |
---|---|
Format: | Book |
Published: |
MDPI AG,
2022-09-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Efficacy, safety, and predictors of response to infliximab therapy for ulcerative colitis
by: Mohamed G Fawaz, et al.
Published: (2022) -
Early Serum Infliximab Levels in Pediatric Ulcerative Colitis
by: Jennifer C. C. deBruyn, et al.
Published: (2021) -
Case Report: Unusual Cause of Fever in Ulcerative Colitis Treated with Infliximab
by: Sha S, et al.
Published: (2023) -
Prediction and Verification of Potential Therapeutic Targets for Non-Responders to Infliximab in Ulcerative Colitis
by: Lyu X, et al.
Published: (2023) -
Proteomic Analysis of Potential Targets for Non-Response to Infliximab in Patients With Ulcerative Colitis
by: Lu Liu, et al.
Published: (2022)